Kastle Therapeutics LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-07-16
- Employees
- 11
- Market Cap
- -
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol
Phase 3
Completed
- Conditions
- Heterozygous FamilialHypercholesterolemia
- Interventions
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 309
- Registration Number
- NCT01475825
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
- First Posted Date
- 2011-08-11
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01414881
- Locations
- 🇺🇸
Columbia-Presbyterian Medical Center, MS Care Center, New York, New York, United States
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers
- First Posted Date
- 2011-02-18
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT01299298
- Locations
- 🇩🇪
FOCUS Clinical Drug Development GmbH, Stresemannallee 6, Neuss, Germany
A Study to Determine the Effects of Multiple Doses of Mipomersen (200 mg SC) on the Pharmacodynamics and Pharmacokinetics of Single-dose Warfarin
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT01133366
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT01090661
- Locations
- 🇺🇸
PPD Development, LP, Austin, Texas, United States
A Study to Evaluate 3 Different Dosing Regimens of Mipomersen Administered Via Subcutaneous Injections to Healthy Volunteers
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2016-08-03
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 84
- Registration Number
- NCT01061814
- Locations
- 🇨🇦
Anapharm, Inc., Montreal,, Quebec, Canada
Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 58
- Registration Number
- NCT00794664
Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients
Phase 3
Completed
- Conditions
- Coronary Heart DiseaseHypercholesterolemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-10-09
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 158
- Registration Number
- NCT00770146
Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects
Phase 2
Completed
- Conditions
- HyperlipidemiasDyslipidemiasMetabolic DiseasesMetabolic DisorderHypercholesterolemiaLipid Metabolism Disorders
- Interventions
- Drug: placebo
- First Posted Date
- 2008-07-01
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT00707746
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease
Phase 3
Completed
- Conditions
- Heterozygous Familial HypercholesterolemiaCoronary Artery Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Kastle Therapeutics, LLC
- Target Recruit Count
- 124
- Registration Number
- NCT00706849
- Locations
- 🇺🇸
ResEvo, LLC, Cuyahoga Falls, Ohio, United States
🇺🇸The Rogosin Institute Comprehensive Lipid Control Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath